Dose-finding study on telithromycin in bacterial pneumonia

Japanese Journal of Chemotherapy

Volumn 51, Issue SUPPL. 1, 2003, Pages 240-254

  Niki, Yoshihito ^a   Watanabe, Akira ^b   Aoki, Nobuki ^c   Kohno, Shigeru ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Department of Internal Medicine   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Ketolides; Telithromycin

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; KETOLIDE; PENICILLIN G; TELITHROMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ERADICATION THERAPY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RELAPSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE;

EID: 0142179257     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bryskier A: New research macrolides and ketolides since 1997. Expert Opinion on Investigational Drugs 8: 1171-1194, 1999
2. Jones R N, Biedenbach D J: Antimicrobial activity of RU-66647, a new ketolide. Diagn Microb Infect Dis 27: 7-12, 1997
3. Biedenbach D J, Barrett M S, Jones R N: Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microb Infect Dis 31: 349-353, 1998
4. Pankuch G A, Visalli M A, Jacobs M R, et al.: Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Anitimicrob Agents Chemotherapy 42: 624-630, 1998
5. Reinert R, Bryskier A, Lutticken R: In vitro activities of the new ketolide antibiotics HMR 3004 and MHR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemotherapy 42: 1509-1511, 1998
6. Hagberg L, Torres A, Van Rensburg D, et al.: Efficacy and tolerability of once-daily therapy with telithromycin compared with high-dose amoxicillin for the treatment of community-acquired pneumonia. Infection 30 (6): 378-386, 2002
7. Roos K, Brunswig-Pitschner C, Kostrica R, et al.: Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 48 (2): 100-108, 2002
8. Aubier M, Aldons P M, Leak A, et al.: Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respiratory Medicine. 96 (11): 862-887, 2002
9. Norrby S R, Rabie W J, Bacart P, et al.: Butticaz -Iroudayassamy E. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis 33: 883-890, 2002
10. Zervos M, Heyder A, Leroy B: Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Research 31: 157-169, 2003
11. Kadota J, Ishimatsu Y, Iwashita T, et al.: Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. Antimicrob Agents Chemother 46: 917-922, 2002
12. National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard. NCCLS publication on. M11-A3. National Committee for Clinical Laboratoty Standards, Villanova, Pa., 1993
13. Japanese source. Chemotherapy 39: 687-689, 1991
14. Japanese source. Chemotherapy 37: 200-225, 1989
15. Japanese source. Chemotherapy 40 (S-3): 121-146, 1992
16. Japanese source. Chemotherapy 40: (S-3): 121-146, 1992
17. Ishida T, Hashimoto T, Arita M, et al.: Etiology of community acquired pneumonia in hospitalized patients. Chest 114: 1588-1593, 1998
18. Guidance for Industry Community-Acquired Pneumonia Developing Antimicrobial Drugs for Treatment U.S: Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), July 1998 http://www.fda.gov/cder/guidance/index.htm